Scpharmaceuticals
Yahoo Finance • last month
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA... Full story
Yahoo Finance • 2 months ago
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmac... Full story
Yahoo Finance • 2 months ago
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be a... Full story
Yahoo Finance • 3 months ago
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced... Full story
Yahoo Finance • last year
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLIN... Full story
Yahoo Finance • last year
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to opt... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives
Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency confirms no additional clinical data r... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapie... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes
BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116.1 million Company to host investor co... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023
BURLINGTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, a... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Call Transcript
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Call Transcript March 22, 2023 PJ Kelleher: Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking state... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Ended Q4 with cash, cash e... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)
BURLINGTON, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
BURLINGTON, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,... Full story
Yahoo Finance • 2 years ago
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,... Full story
